Wellgistics Health, Inc. (NASDAQ: WGRX) announced a non‑exclusive, non‑binding Letter of Intent to acquire Neuritek Therapeutics, a neuroscience‑focused research organization, in an all‑stock transaction valued at approximately $105 million. The LOI is preliminary and subject to due diligence and definitive agreements.
The announcement comes as Wellgistics faces significant financial distress. The company reported a net loss of $101.27 million for the full year ended December 31, 2025, compared with a net loss of $6.86 million the prior year, and revenue of $23.34 million, up from $18.13 million. Its current ratio sits at 0.39, and a Nasdaq delisting notice has been issued for failing to meet the minimum bid price requirement. An auditor’s “going‑concern” opinion underscores the severity of the liquidity and leverage challenges. The acquisition is therefore a strategic shift aimed at diversifying revenue streams and expanding Wellgistics’ platform beyond its core pharmacy‑distribution business.
Neuritek Therapeutics is developing an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1) for post‑traumatic stress disorder (PTSD). The lead candidate, NRTKOOI (also referred to as NTRK001), is currently in Phase 2 clinical trials. The deal would give Wellgistics access to a novel therapeutic pipeline and a foothold in the mental‑health market, potentially creating new revenue opportunities that could offset the company’s current financial headwinds.
The strategic rationale for the transaction is to broaden Wellgistics’ revenue base and leverage its technology‑enabled distribution network to support the commercialization of Neuritek’s pipeline. By integrating a neuroscience research organization, Wellgistics could combine its pharmacy‑distribution expertise with a drug‑development portfolio, creating synergies that may accelerate market entry for future products.
Management has emphasized the company’s focus on operational execution and balance‑sheet improvement. President and interim CEO Prashant Patel said, "Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper‑focused operational execution phase. In 2026 we will focus squarely on the implementation of our EinsteinRx™ AI platform into pharmacy client point of sale systems, onboarding and increasing the percentage of our 6,500+ independent pharmacy customers that convert into our official Wellgistics pharmacy network (the 'Wellgistics Pharmacy Network')." Chief Financial Officer Mark DiSiena added, "This quarter marks an inflection point where disciplined execution and balance sheet improvements begin to align with our long‑term growth strategy, setting the stage for results that extend far beyond today's numbers. We are reshaping the company into a more resilient, technology‑driven, and innovative organization." Chief Executive Officer Brian Norton noted, "Wellgistics Health is positioned to expand access through direct‑to‑patient delivery models. We've built the infrastructure, strengthened the balance sheet, and continue to expand our national network of pharmacies and manufacturers. Our focus now is closing strategic funding to accelerate growth as we deliver a faster, smarter, and more direct path to patients while keeping community pharmacies at the center of care."
The market has reacted negatively to the announcement, reflecting concerns about Wellgistics’ financial fragility. The company’s stock is trading at $0.14, down 97% over the past year, and the Nasdaq delisting notice remains a looming risk. Investors are weighing the potential upside of a diversified revenue model against the significant headwinds posed by the company’s liquidity constraints and ongoing financial losses.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.